STAT News · Scour

STAT+: Are analysts too quick to gloss over Lilly’s liver case?

statnews.com·1w

STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more

statnews.com·1w

What you need to know about hantavirus (don’t panic)

statnews.com·1w

STAT+: Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease

statnews.com·1w

Opinion: The ‘brain drain’ narrative about health professionals misses half of the story

statnews.com·1w

STAT+: Top lawmaker takes aim at doctor lobby, linking AMA’s billing codes to fraud fight

statnews.com·1w

Opinion: The cruise ship hantavirus outbreak is a warning sign to the U.S.

statnews.com·1w

STAT+: Johnson & Johnson advances IBD therapy, despite trial miss

statnews.com·1w

STAT+: French regulator fines Novo and Lilly over weight loss ad campaigns

statnews.com·1w

Opinion: Mifepristone court ruling makes drug development riskier for everyone

statnews.com·1w

Supreme Court restores access to abortion pill mifepristone through telehealth, mail, and pharmacies

statnews.com·1w

Researchers urge study of paternal deaths, though a new paper finds fatherhood is protective

statnews.com·1w

STAT+: Pump the brakes on AI, buddy; and deposition deadlock

statnews.com·1w

UCB to acquire maker of antibody treatments for autoimmune diseases

statnews.com·1w

What to know about hantavirus, the illness suspected in a cruise ship outbreak

statnews.com·1w

STAT+: Pharmalittle: We’re reading about an abortion pill controversy, another UCB deal, and more news

statnews.com·1w

Federal court blocks mailing of mifepristone

statnews.com·1w

STAT+: Biotech raises $42 million to run Huntington’s disease trial

statnews.com·1w

Opinion: Are blue zones real? Answering that question is harder than ever

statnews.com·1w

Immigration changes are driving foreign researchers to leave the U.S.

statnews.com·1w

Log in to enable infinite scrolling